Haematologist Dr Sue Pavord was one of the jab’s biggest supporters, but she knew something was wrong when she saw the ...

Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines ...

AstraZeneca will invest 820 million Canadian dollars, equivalent to $570.3 million, to facilitate a move to a larger office in the Toronto metro area. The Anglo-Swedish pharmaceutical giant said ...

AstraZeneca (NASDAQ:AZN), a global pharmaceutical firm, has announced a C$820 million (US$570 million) investment in Canada, ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

AstraZeneca is expanding its boot print in Canada with a $570 million investment designed to create 700 jobs. | AstraZeneca is expanding its boot print in Canada with a $570 million investment ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...

Invest Ontario is partnering with AstraZeneca (AZN) to expand the company’s global R&D hub in Mississauga. This C$820M investment ...